Current Controversies and Challenging Cases in HBV Management
  • CME
  • CE

In this video capture of a roundtable session from the 2019 CCO Hepatitis Annual Meeting, experts discuss key issues in the care of patients at risk of or with HBV infection, including when to consider nucleos(t)ide cessation, HCC screening, antiviral prophylaxis, and treatment of immune-tolerant disease.
Ira M. Jacobson, MD
Program Director
Paul Y. Kwo, MD
Marion G. Peters, MD, FRACP
Nancy Reau, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: August 28, 2019 Expiration: August 27, 2020
Multimedia Current Controversies and Challenging Cases in HBV Management
This program is divided into short segments. After reviewing all segments, click the Claim Credit button to complete the CME/CE posttest and evaluation.
When Can We Consider Stopping HBV Therapy?
Learn which parameters influence the decision to continue vs stop HBV therapy. Consider the case of a noncirrhotic young female with HBeAg-positive disease who seroconverts with detectable anti-HBe after 2 years of nucleos(t)ide treatment.
Launch When Can We Consider Stopping HBV Therapy?
Which Patients With CHB Should Be Screened for HCC?
Gain a better understanding of the factors that associate with HCC risk as well as current recommendations regarding the frequency and methodology used to screen at-risk patients.
Launch Which Patients With CHB Should Be Screened for HCC?
Which Patients Receiving Immunosuppressive Therapy Need Antiviral Prophylaxis?
Review guidance on the recommended tests to gauge risk of HBV reactivation during immunosuppressive, cytotoxic, or immunomodulatory therapy. Faculty discuss when monitoring may be appropriate vs immediate administration of HBV prophylaxis.
Launch Which Patients Receiving Immunosuppressive Therapy Need Antiviral Prophylaxis?
When Should Patients With Immune-Tolerant CHB Be Treated?
Examine the criteria for initiating therapy in HBeAg-positive patients with high viral load but normal or minimally elevated ALT. Faculty debate how pregnancy intent may affect these management decisions.
Launch When Should Patients With Immune-Tolerant CHB Be Treated?
Question and Answer Session
Watch as the expert panel fields questions from the audience on optimal management of patients with chronic hepatitis B.
Launch Question and Answer Session

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply key guidelines and study data to ensure appropriate, individualized management of chronic hepatitis B, including when to start and stop therapy
  • Effectively prevent HBV reactivation in patients undergoing immunosuppressive therapy
  • Determine which patients with HBV infection require screening for hepatocellular carcinoma

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AbbVie
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Ira M. Jacobson, MD

Director of Hepatology
Department of Medicine
NYU School of Medicine
New York, New York

Ira M. Jacobson, MD, has disclosed that he has received consulting fees from AbbVie, Arrowhead, Assembly Biosciences, Bristol-Myers Squibb, Gilead Sciences, Intercept, Janssen, Merck, Novo Nordisk, Siemens, and Springbank and funds for research support from Assembly Biosciences, Bristol-Myers Squibb, Enanta, Genfit, Gilead Sciences, and Janssen.

Faculty

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul Y. Kwo, MD, has disclosed that he has received consulting fees from AbbVie, Conatus, Dova, Edigene, Eisai, Ferring, Gilead Sciences, Quest, and Surrozen; has received funds for research support from Allergan, Assembly Biosciences, Gilead Sciences, La Jolla, and Target PharmaSolutions; has ownership interest in Durect; and has served on data and safety monitoring boards for Durect and Janssen.
Marion G. Peters, MD, FRACP

Chief of Hepatology Research
Professor of Medicine, Gastroenterology
University of California, San Francisco
San Francisco, California

Marion G. Peters, MD, FRACP, has disclosed that her spouse is employed by Hoffmann-La Roche.
Nancy Reau, MD

Professor of Medicine
Chief,
Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Nancy Reau, MD, has disclosed that she has received consulting fees from Abbott, AbbVie, Gilead Sciences, and Merck and that she has received salary from AASLD-CLD.

Staff

Megan K. Murphy, PhD

Associate Scientific Director

Megan K. Murphy, PhD, has no relevant conflicts of interest to report.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant conflicts of interest to report.
Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD, has no relevant conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hepatologists, gastroenterologists, infectious diseases clinicians, registered nurses, pharmacists, and other healthcare professionals involved in the care of patients with viral hepatitis.

Goal

The goal of this activity is to improve participants’ competence in addressing the most important and most current challenges in viral hepatitis management by providing a tightly focused update on recent advances and key clinical issues encountered in the clinic.

Physician Continuing Medical Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

1.0 contact hour may be earned for successful completion of this activity.

Pharmacist Continuing Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program is assigned ACPE Universal Activity 0797-9999-19-092-H01-P. This program is designated for up to 1.0 contact hour (0.10 CEUs) of continuing pharmacy education credit.

Type of Activity Application

For Pharmacists: Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 28, 2019, through August 27, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

关于医生监测和治疗慢性 HBV 感染的患者特定 AASLD、EASL 和 APASL 建议。Kosh Agarwal,Paul Kwo,Grace Wong。

Kosh Agarwal, MD Paul Y. Kwo, MD Grace LH Wong, MD Released: September 27, 2019

Audio from Dr. Ira Jacobson on evidence for treating patients with immune-tolerant CHB and whether ALT 2 or more x ULN should define HBV treatment candidacy

Ira M. Jacobson, MD Released: September 5, 2019

CME/CE/CPE-certified video on strategies for simplifying HCV management with Jordan J. Feld, MD, MPH, from CCO Hepatitis Annual Meeting

Ira M. Jacobson, MD
Program Director
Jordan J. Feld, MD, MPH
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.7 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: August 23, 2019 Expiration: August 22, 2020

Audio commentary from Dr. Robert Brown on when to treat chronic hepatitis B, what drugs to use, and when to consider stopping HBV therapy.

Robert S. Brown, Jr., MD, MPH Released: August 14, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?